Matthew R Gingo1, Mehdi Nouraie1, Cathy J Kessinger1, Ruth M Greenblatt2,3, Laurence Huang3, Eric C Kleerup4, Lawrence Kingsley5, Deborah K McMahon1, Alison Morris1,6. 1. 1 Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 2. 2 University of California San Francisco School of Pharmacy, San Francisco, California. 3. 3 Department of Medicine, University of California San Francisco School of Medicine, San Francisco, California. 4. 4 Departments of Clinical Pharmacology, Epidemiology, and Biostatistics, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California. 5. 5 Department of Immunology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania; and. 6. 6 Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Abstract
RATIONALE: Human immunodeficiency virus (HIV) infection is associated with pulmonary disease and worse lung function, but the relationship of lung function with survival in HIV is unknown. OBJECTIVES: To determine whether lung function is associated with all-cause mortality in HIV-infected individuals. METHODS: HIV-infected participants from cohorts in three locations underwent pre- and post-bronchodilator spirometry and determination of single-breath diffusing capacity of the lung for carbon monoxide (DlCO) in 2008-2009, computed tomographic (CT) scanning of the chest for quantitative emphysema and airway measures, and echocardiography for estimated left ventricular systolic and diastolic function and tricuspid regurgitant velocity. Bivariate analysis and multivariable Cox proportional hazards models were used to determine whether decreased lung function was independently associated with increased all-cause mortality. Models were adjusted for covariates including age, sex, body mass index, smoking status, self-reported hepatitis C status, HIV viral levels, CD4+ T-cell counts, hemoglobin, antiretroviral therapy, and illicit drug use. RESULTS: Overall, 396 HIV-infected participants underwent pulmonary function testing. Thirty-two participants (8%) died during a median follow-up period of 69 months. A post-bronchodilator FEV1-to-FVC ratio less than 0.7 (hazard ratio [HR], 2.47; 95% confidence interval [CI], 1.10-5.58) and a DlCO less than 60% (HR, 2.28; 95% CI, 1.08-4.82) were independently associated with worse mortality. Also, hepatitis C (HR, 2.68; 95% CI, 1.22-5.89) and baseline plasma HIV RNA level (HR per ln RNA copies/ml, 1.50; 95% CI, 1.22-1.86) were associated with mortality in HIV-infected participants. The only CT or echocardiographic measure associated with greater mortality in univariate analysis was greater wall thickness of medium-sized airways (HR for wall area percent, 1.08; 95% CI, 1.00-1.18; P = 0.051), but none of the CT or echocardiogram measures were associated with mortality in multivariable analysis. CONCLUSIONS: Airflow obstruction and impaired diffusing capacity appear to be associated with all-cause mortality in HIV-infected persons over an average of 6 years of follow-up. These data highlight the importance of lung dysfunction in HIV-infected persons and should be confirmed in larger cohorts and with extended follow-up periods. Clinical trial registered with www.clinicaltrials.gov (NCT00869544, NCT01326572).
RATIONALE: Human immunodeficiency virus (HIV) infection is associated with pulmonary disease and worse lung function, but the relationship of lung function with survival in HIV is unknown. OBJECTIVES: To determine whether lung function is associated with all-cause mortality in HIV-infected individuals. METHODS:HIV-infectedparticipants from cohorts in three locations underwent pre- and post-bronchodilator spirometry and determination of single-breath diffusing capacity of the lung for carbon monoxide (DlCO) in 2008-2009, computed tomographic (CT) scanning of the chest for quantitative emphysema and airway measures, and echocardiography for estimated left ventricular systolic and diastolic function and tricuspid regurgitant velocity. Bivariate analysis and multivariable Cox proportional hazards models were used to determine whether decreased lung function was independently associated with increased all-cause mortality. Models were adjusted for covariates including age, sex, body mass index, smoking status, self-reported hepatitis C status, HIV viral levels, CD4+ T-cell counts, hemoglobin, antiretroviral therapy, and illicit drug use. RESULTS: Overall, 396 HIV-infectedparticipants underwent pulmonary function testing. Thirty-two participants (8%) died during a median follow-up period of 69 months. A post-bronchodilator FEV1-to-FVC ratio less than 0.7 (hazard ratio [HR], 2.47; 95% confidence interval [CI], 1.10-5.58) and a DlCO less than 60% (HR, 2.28; 95% CI, 1.08-4.82) were independently associated with worse mortality. Also, hepatitis C (HR, 2.68; 95% CI, 1.22-5.89) and baseline plasma HIV RNA level (HR per ln RNA copies/ml, 1.50; 95% CI, 1.22-1.86) were associated with mortality in HIV-infectedparticipants. The only CT or echocardiographic measure associated with greater mortality in univariate analysis was greater wall thickness of medium-sized airways (HR for wall area percent, 1.08; 95% CI, 1.00-1.18; P = 0.051), but none of the CT or echocardiogram measures were associated with mortality in multivariable analysis. CONCLUSIONS:Airflow obstruction and impaired diffusing capacity appear to be associated with all-cause mortality in HIV-infected persons over an average of 6 years of follow-up. These data highlight the importance of lung dysfunction in HIV-infected persons and should be confirmed in larger cohorts and with extended follow-up periods. Clinical trial registered with www.clinicaltrials.gov (NCT00869544, NCT01326572).
Authors: Philip T Diaz; Mark D Wewers; Eric Pacht; Janice Drake; Haikady N Nagaraja; Thomas L Clanton Journal: Chest Date: 2003-06 Impact factor: 9.410
Authors: Bin Zheng; Joseph K Leader; Jessica M McMurray; Sang Cheol Park; Carl R Fuhrman; David Gur; Frank C Sciurba Journal: Med Phys Date: 2007-07 Impact factor: 4.071
Authors: Gavin C Donaldson; John R Hurst; Christopher J Smith; Richard B Hubbard; Jadwiga A Wedzicha Journal: Chest Date: 2009-12-18 Impact factor: 9.410
Authors: Matthew S Freiberg; Chung-Chou H Chang; Melissa Skanderson; Kathleen McGinnis; Lewis H Kuller; Kevin L Kraemer; David Rimland; Matthew B Goetz; Adeel A Butt; Maria C Rodriguez Barradas; Cynthia Gibert; David Leaf; Sheldon T Brown; Jeffrey Samet; Lewis Kazis; Kendall Bryant; Amy C Justice Journal: Circ Cardiovasc Qual Outcomes Date: 2011-06-28
Authors: Priscilla Y Hsue; Steven G Deeks; Husam H Farah; Swapna Palav; Samira Y Ahmed; Amanda Schnell; Allison B Ellman; Laurence Huang; Sheila C Dollard; Jeffrey N Martin Journal: AIDS Date: 2008-04-23 Impact factor: 4.177
Authors: David M MacDonald; Anne C Melzer; Gary Collins; Anchalee Avihingsanon; Kristina Crothers; Nicholas E Ingraham; Henry Mugerwa; Matti Ristola; Jonathan Shuter; Ken M Kunisaki Journal: J Acquir Immune Defic Syndr Date: 2018-11-01 Impact factor: 3.731
Authors: David M MacDonald; Alexander D Zanotto; Gary Collins; Jason V Baker; Marcin Czarnecki; Eliana Loiza; Daniel E Nixon; Vasileios Papastamopoulos; Chris H Wendt; Robin Wood; Ken M Kunisaki Journal: AIDS Date: 2019-03-15 Impact factor: 4.177
Authors: Mariah M Kalmin; Daniel Westreich; Bradley M Drummond; Jing Sun; Shruti H Mehta; Gregory D Kirk Journal: AIDS Date: 2021-07-15 Impact factor: 4.632
Authors: Amanda K Jan; Julia V Moore; Richard J Wang; Maggie Mcging; Carly K Farr; Daniela Moisi; Marlena Hartman-Filson; Robert Kerruish; Diane Jeon; Eula Lewis; Kristina Crothers; Michael M Lederman; Peter W Hunt; Laurence Huang Journal: AIDS Date: 2021-06-01 Impact factor: 4.632
Authors: Kristin R V Harrington; Bashar S Staitieh; Minh Ly T Nguyen; Jonathan A Colasanti; Jieri Sumitani; Vincent C Marconi; Sara C Auld Journal: AIDS Patient Care STDS Date: 2021-07 Impact factor: 5.944